An overview of bacillus anthracis bacteria, one of the most important biological agents
Abstract
So far, more than 1400 human pathogens have been identified. Of this number, more than 60% have a common origin between humans and animals, which infect humans through animal reservoirs. These diseases include viruses such as influenza, less common (but fatal) diseases such as rabies, and neglected parasites such as echinococcosis and cysticercosis. The subcategory of bacterial zoonoses also varies, with pathogens common in industrial settings (including salmonella and bartonella henselae, the causative agent of cat-scratch disease) and diseases more associated with impoverished tropical regions (such as melioidosis and leptospirosis). In this article, we will examine the bacillus anthracis bacteria that causes anthrax, which is one of the most important bacteria (the cause of zoonotic diseases) and is also considered one of the agents of bioterrorism.
Keywords
Full Text:
PDFReferences
Taylor LH, Latham SM, woolhouse MEJ. Risk factors for human disease emergence. Woolhouse MEJ, Dye C, eds. Philosophical Transactions of the Royal Society of London Series B: Biological Sciences. 2001; 356(1411): 983-989. doi: 10.1098/rstb.2001.0888
Barras V, Greub G. History of biological warfare and bioterrorism. Clinical Microbiology and Infection. 2014; 20(6): 497-502. doi: 10.1111/1469-0691.12706
Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk Anthrax Outbreak of 1979. Science. 1994; 266(5188): 1202-1208. doi: 10.1126/science.7973702
Jaton K, Greub G. Clinical microbiologists facing an anthrax alert. Clinical Microbiology and Infection. 2014; 20(6): 503-506. doi: 10.1111/1469-0691.12682
Vieira AR, Salzer JS, Traxler RM, et al. Enhancing Surveillance and Diagnostics in Anthrax-Endemic Countries. Emerging Infectious Diseases. 2017; 23(13). doi: 10.3201/eid2313.170431
Bush LM, Abrams BH, Beall A, et al. Index Case of Fatal Inhalational Anthrax Due to Bioterrorism in the United States. New England Journal of Medicine. 2001; 345(22): 1607-1610. doi: 10.1056/nejmoa012948
Hughes JM, Gerberding JL. Anthrax Bioterrorism: Lessons Learned and Future Directions. Emerging Infectious Diseases. 2002; 8(10): 1013-1014. doi: 10.3201/eid0810.020466
Friebe S, Van der Goot F, Bürgi J. The Ins and Outs of Anthrax Toxin. Toxins. 2016; 8(3): 69. doi: 10.3390/toxins8030069
Adalja AA, Toner E, Inglesby TV. Clinical Management of Potential Bioterrorism-Related Conditions. Longo DL, ed. New England Journal of Medicine. 2015; 372(10): 954-962. doi: 10.1056/nejmra1409755
Shafazand S. When bioterrorism strikes: diagnosis and management of inhalational anthrax. Seminars in Respiratory Infections. 2003; 18: 134-145.
Doganay M, Metan G, Alp E. A review of cutaneous anthrax and its outcome. Journal of Infection and Public Health. 2010; 3(3): 98-105. doi: 10.1016/j.jiph.2010.07.004
Sirisanthana T, Brown AE. Anthrax of the Gastrointestinal Tract. Emerging Infectious Diseases. 2002; 8(7): 649-651. doi: 10.3201/eid0807.020062
Purcell B, Worsham P, Friedlander A. Anthrax. In: Dembek ZS (editor). Medical aspects of biological warfare. Falls Church, VA: Borden Institute and US Army Office of the Surgeon General; 2007.
Barakat LA. Fatal Inhalational Anthrax in a 94-Year-Old Connecticut Woman. JAMA. 2002; 287(7): 863. doi: 10.1001/jama.287.7.863
Abramova FA, Grinberg LM, Yampolskaya OV, et al. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proceedings of the National Academy of Sciences. 1993; 90(6): 2291-2294. doi: 10.1073/pnas.90.6.2291
Bower WA, Hendricks K, Pillai S, et al. Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident. MMWR Recommendations and Reports. 2015; 64(4): 1-22. doi: 10.15585/mmwr.rr6404a1
Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults. Emerging Infectious Diseases. 2014; 20(2). doi: 10.3201/eid2002.130687
Katharios-Lanwermeyer S, Holty JE, Person M, et al. Identifying Meningitis During an Anthrax Mass Casualty Incident: Systematic Review of Systemic Anthrax Since 1880. Clinical Infectious Diseases. 2016; 62(12): 1537-1545. doi: 10.1093/cid/ciw184
Meaney-Delman D, Zotti ME, Creanga AA, et al. Special Considerations for Prophylaxis for and Treatment of Anthrax in Pregnant and Postpartum Women. Emerging Infectious Diseases. 2014; 20(2). doi: 10.3201/eid2002.130611
Walsh JJ, Pesik N, Quinn CP, et al. A Case of Naturally Acquired Inhalation Anthrax: Clinical Care and Analyses of Anti-Protective Antigen Immunoglobulin G and Lethal Factor. Clinical Infectious Diseases. 2007; 44(7): 968-971. doi: 10.1086/512372
Webster JI, Moayeri M, Sternberg EM. Novel Repression of the Glucocorticoid Receptor by Anthrax Lethal Toxin. Annals of the New York Academy of Sciences. 2004; 1024(1): 9-23. doi: 10.1196/annals.1321.003
Inglesby TV, O’Toole T, Henderson DA, et al. Anthrax as a Biological Weapon, 2002. JAMA. 2002; 287(17): 2236. doi: 10.1001/jama.287.17.2236
Yamamoto BJ, Shadiack AM, Carpenter S, et al. Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity. Antimicrobial Agents and Chemotherapy. 2016; 60(10): 5787-5795. doi: 10.1128/aac.00972-16
Yamamoto BJ, Shadiack AM, Carpenter S, et al. Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax. Antimicrobial Agents and Chemotherapy. 2016; 60(10): 5796-5805. doi: 10.1128/aac.01102-16
Migone TS, Bolmer S, Zhong J, et al. Added Benefit of Raxibacumab to Antibiotic Treatment of Inhalational Anthrax. Antimicrobial Agents and Chemotherapy. 2015; 59(2): 1145-1151. doi: 10.1128/aac.04606-14
Kummerfeldt C. Raxibacumab: potential role in the treatment of inhalational anthrax. Infection and Drug Resistance. Published online April 2014: 101. doi: 10.2147/idr.s47305
Kammanadiminti S, Patnaikuni RK, Comer J, et al. Combination Therapy with Antibiotics and Anthrax Immune Globulin Intravenous (AIGIV) Is Potentially More Effective than Antibiotics Alone in Rabbit Model of Inhalational Anthrax. PLoS ONE. 2014; 9(9): e106393. doi: 10.1371/journal.pone.0106393
DOI: https://doi.org/10.18686/pas.v5i1.2227
Refbacks
- There are currently no refbacks.
